Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Scandinavian Journal of Pain

Official Journal of the Scandinavian Association for the Study of Pain

Editor-in-Chief: Breivik, Harald


CiteScore 2018: 0.85

SCImago Journal Rank (SJR) 2018: 0.494
Source Normalized Impact per Paper (SNIP) 2018: 0.427

Online
ISSN
1877-8879
See all formats and pricing
More options …
Volume 15, Issue 1

Issues

Opioids and the gut; not only constipation and laxatives

Asbjørn Mohr Drewes
  • Corresponding author
  • Department of Gastroenterology & Hepatology, Clinical Institute, Aalborg University Hospital, Mølleparkvej, DK-9000, Aalborg Denmark
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-04-01 | DOI: https://doi.org/10.1016/j.sjpain.2017.01.010

References

  • [1]

    Søndergaard J, Nordahl-Christensen H, Ibsen R, Ejg Jarbøl D, Kjellberg J. Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: a nationwide register-based cohort study in Denmark. Scand J Pain 2017;15:83–90.Web of SciencePubMedCrossrefGoogle Scholar

  • [2]

    Bell TJ, Panchal SJ, Miaskowski C, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35–42.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [3]

    Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Ther Adv Gastroenterol 2015;8:360–72.CrossrefWeb of ScienceGoogle Scholar

  • [4]

    Dunlop W, Uhl R, Khan I, Taylor A, Barton G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012;15:564–75.CrossrefPubMedGoogle Scholar

  • [5]

    Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, Riley J, Dahan A. Differences between opioids. Pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol 2013;75:60–78.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [6]

    Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician 2008;11:S105–20.PubMedGoogle Scholar

  • [7]

    Drewes AM, Munkholm P, Simrén M, Breivik H, Kongsgaard UE, Hatlebakk JG, Agreus L, Christrup LL. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction—recommendations of the Nordic Working Group. Scand J Pain 2016;11:111–22.Web of ScienceCrossrefGoogle Scholar

  • [8]

    Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599–608.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [9]

    Müller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, Emmanuel A, Laroche F, Meissner W, Morlion B. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med 2016, http://dx.doi.org/10.1093/pm/pnw255, pii: pnw255.Web of Science

  • [10]

    Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Man 2008;35:103–13.CrossrefGoogle Scholar

  • [11]

    Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract 2016, http://dx.doi.org/10.1111/papr.12535.PMID:27860208.Web of Science

  • [12]

    Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005;17:157–65.PubMedCrossrefGoogle Scholar

  • [13]

    Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe non-cancer pain. Curr Med Res Opin 2008;24:3503–12.CrossrefGoogle Scholar

  • [14]

    Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. NEJM 2014;370:2387–96.PubMedCrossrefGoogle Scholar

  • [15]

    Gustavsson A, Bjorkman J, Ljungcrantz C, Rhodin A, Rivano-Fischer M, Sjolund KF, Mannheimer C. Socio-economic burden of patients with a diagnosis related to chronic pain – register data of 840,000 Swedish patients. Eur J Pain 2012;16:289–99.Web of SciencePubMedCrossrefGoogle Scholar

About the article

Fax: +45 99 32 25 03.


Published Online: 2017-04-01

Published in Print: 2017-04-01


Conflict of interest: AMD has received unrestricted funds for research and speaker fees from Mundipharma, AstraZeneca and Kyowa Kirin.


Citation Information: Scandinavian Journal of Pain, Volume 15, Issue 1, Pages 81–82, ISSN (Online) 1877-8879, ISSN (Print) 1877-8860, DOI: https://doi.org/10.1016/j.sjpain.2017.01.010.

Export Citation

© 2017 Scandinavian Association for the Study of Pain.Get Permission

Comments (0)

Please log in or register to comment.
Log in